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Abstract
Aim   
This paper presents an overview of the main components of randomised controlled trials and identifies key issues, which should be considered during their design and management. 

Background
Randomised controlled trials are considered to be the gold standard for determining causality, and can provide high quality evidence to inform nursing practice. 

Data sources/Review methods
A search of online databases and websites was undertaken to identify relevant contemporary literature to inform the discussion.  

Discussion/Conclusion
Conducting a robust randomised controlled trial can present researchers with numeorus challenges and practical considerations. The importance of taking account of the CONSORT guidelines during their design, conduct and reporting is emphasised.     
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Randomised Controlled Trials (RCTs) are quantitative, comparative, controlled experiments during which two or more randomly allocated interventions (one being a control) are studied in a series of individuals. They enable a specific hypothesis to be tested, i.e. ‘a’ is better than ‘b’, but are designed to assume there is no difference at the start of a trial, the null hypothesis (Popper 1959). RCTs are widely viewed as the gold standard for determining causality and they make an important contribution to the evaluation of effective health care interventions, including those pertinent to nursing (Richards and Hamers 2009, Vedelø and Lomborg 2011). Despite these benefits, the complexities associated with RCTs can make it difficult for trials of sound methodological quality to be conducted (Moher et al 2010). This paper provides an introduction to the key elements that should be considered during the design and conduct of a high quality RCT.    

Classification of RCTs
Two main types of RCT exist: explanatory and pragmatic (Table 1). Explanatory RCTs measure efficacy (the capacity to produce an effect) and test hypotheses under highly controlled conditions. In contrast, pragmatic trials measure effectiveness (whether something works under real life conditions)  (Roland and Torgerson 1998, Godwin et al 2003). Pragmatic trials enable a broad range of outcomes, meaningful to clinicians, service users, policy makers and funders to be assessed (Tunis et al 2003, Zwarenstein et al 2008, Treweek and Zwarenstein 2009). They are therefore well suited to the evaluation of nursing interventions. Non-inferiority trials (where an intervention is tested to see if it is at least as good as a control) may be considered as a third classification, or as a subset of one of the other two.
Insert Table 1 here: RCT classifications 
Participants can be exposed to the intervention(s) in different ways. Most commonly, parallel designs are used (Moher et al 2010), where participants are randomised to receive only one of the trial interventions (Figure 1). 
Insert Figure 1 here: Parallel design

In contrast, in a cross over design participants receive all interventions (Figure 2), but will be randomised to the order in which they receive them, often with a ‘washout’ (period of time between interventions) to prevent carry over effects from the preceding intervention (Jadad and Enkin 2007). 
Insert Figure 2 here: Cross over design

Alternatively, a factorial design (Figure 3) enables the comparison of two or more interventions (for example, antipyretics and cooling blankets) individually and in combination, offering the added opportunity to investigate any potential interactions (Jadad and Enkin 2007). 
Insert Figure 3 here: Factorial design

It is also possible for a trial to be conducted with one participant (n=1 trial). In such cases, the identified patient receives both the intervention(s) and control using a cross over design. Although such trials provide strong evidence of effectiveness for the individual, they are not generalisable, and are therefore used for rare conditions or situations.

Validity
An essential aspect of conducting a RCT is their internal and external validity. Internal validity is the extent to which differences between the intervention and control groups can be attributed to the intervention and not an alternative explanation (Godwin et al 2003). External validity relates to whether study conclusions can be confidently generalised to a different population group (Godwin et al 2003, Rothwell 2005, Trochim 2006) with the same condition or situation. Sound research conclusions depend upon the identification and management of threats to validity.

International multi-centre trials have greater external validity than single centre studies (Rothwell 2005). However, the more heterogeneous the sample, the harder it is to control internal validity, particularly across different health care systems and countries. Therefore, there has to be a balance between the pragmatic and explanatory trial.

With pragmatic trials often including a diverse ‘real life’ population, their external validity is maximised (Godwin et al 2003). Their internal validity can, however, be compromised by the use of less stringent inclusion and exclusion criteria, potentially increasing the number of confounding factors. Bias induced by personal preference, the environment and the actions of staff, for example deviations from the research protocol may also be more likely in a pragmatic trial (Vedelø and Lomborg 2011). Poor internal validity will, in turn, compromise the external validity of a study. To maximise internal validity, several key features need to be present. These include randomisation, study power, intention to treat and appropriate data analysis. These features are described throughout the rest of this paper. 

Randomisation
A defining feature of all RCTs is the process of randomisation (Hulley et al 2007, Jadad and Enkin 2007). Participants are randomly allocated to a specific intervention group (study arm) or to a control (control arm), enabling comparisons in outcomes between the two groups to be made. Randomisation assumes that every participant has an equal chance of being allocated to all arms of the trial, and that individual differences between participants are evenly distributed between groups (Richards and Hamers 2009). 

Where available, a current accepted standard should be provided to the control arm, because it is unethical not to use an intervention already known to work, plus you want to know whether or not the new intervention is more effective. If a ‘gold standard’ exists, an equivalence or non-inferiority trial (see Table 1) might be designed (Hulley et al 2007, Snappin 2000). 
 
Randomisation procedures
The main threats to the internal validity of a RCT are selection and ascertainment bias. Selection bias can occur if potentially eligible participants are selected based on a variable (such as age, diagnosis) associated with the outcome (Torgerson and Torgerson 2008), as a result of prior knowledge or influence. Selection bias can be avoided by effective randomisation (Richards and Hamers 2009). 

After allocation of an individual to either intervention or control, ascertainment bias, where results or conclusions are influenced by knowledge of which intervention each participant is receiving, may occur. Such bias can be introduced by the participant, those implementing the intervention and/or those collecting and reporting the data. Ascertainment bias can be minimised by careful attention to the overall design and conduct of the trial, for example ensuring that the same person collects all data and careful training of staff in trial procedures. 

Accurate reporting of procedures helps demonstrate how different biases were avoided or reduced, thus increasing confidence in trial results (Moher et al 2010).    

Sequence generation
Sequence generation (construction of the order in which participants will receive either intervention or control) is the first step in the randomisation process. It can be achieved in a number of ways (Table 2), the key factors to avoid selection bias being: (1) the method must not be predictable and (2) the allocation should be concealed from those involved in the trial (Beller et al 2002). 
Insert Table 2 here: Sequence generation 

Simple randomisation techniques, equivalent to the tossing of a fair coin (using computer generated random tables) are efficient and effective, particularly in larger trials (>200 participants) (Schulz and Grimes 2002e), where homogenous groups of similar size are likely to be achieved (Beller et al 2002). 
 
Where sample sizes are smaller and unlikely to produce equal allocations with simple randomisation, restricted randomisation procedures may be used. A common example is block randomisation (Table 2), where blocks, containing equal numbers of intervention and control are constructed for a specified number of participants. A random number sequence then determines the order in which blocks are used. 

Block randomisation enables balanced allocation to be achieved at the end of each block (Beller et al 2002), but can be particularly risky in open trials where future allocations are more predictable (Schulz and Grimes 2002e). If used, the allocation order for each block must be random, and allocation ratios, methods and block sizes should all be reported (Schulz and Grimes 2002a, Farrokhyar et al 2010). Stratification based on predefined variables may also be used to control for important prognostic factors (Beller et al 2002, Schulz and Grimes 2002a, Nichol et al 2010). 

Dynamic (adaptive) randomisation techniques, equivalent to the use of ‘biased coin’ tossing are other options. In contrast to simple and block randomisation, dynamic randomisation methods (Table 2), such as ‘urn’ randomisation (Stout et al 1994, Ivanova and Rosenberger 2000) and minimisation (Pocock and Simon 1975, Han et al 2009), allocate participants throughout the trial, in order to balance groups (Beller et al 2002).

Allocation concealment 
Allocation concealment is the technique used to implement the allocation sequence (Schulz and Grimes 2002b) and avoid selection bias. Best practice dictates that none of the trial investigators should have prior knowledge of treatment allocation, or control over the order in which participants are randomised (Forder et al 2005). Failed allocation concealment can result in over exaggerated treatment effects of up to 40% (Schulz and Grimes 2002b). An independent person should have sole access to the randomisation schedule (also prepared by an external person), which should be stored in a secure location away from the trial site, and allocation should be revealed only after recruitment of a participant (Schulz and Grimes 2002b, Farrokhyar et al 2010). 

Allocation concealment is easier to achieve in multi-centre trials, which employ central randomisation techniques, but is also possible in single centre trials (Forder et al 2005). For example, externally pre-prepared, tamper proof envelopes containing the allocation can be used. These minimum methodological standards should, however, be exceeded wherever possible (Schulz and Grimes 2002b, Moher et al 2010). 

Blinding 
Blinding (or masking as it is sometimes known) conceals knowledge of the group to which an individual has been allocated from those involved in the trial. Blinding helps prevent ascertainment bias and protects the randomisation sequence after allocation (Schulz and Grimes 2002c). It can be achieved at various levels (see Table 3), and is an important distinctive feature of RCTs (Schulz and Grimes 2002c). 
Insert Table 3 here: Levels of blinding (according to Schulz and Grimes 2002c) 

A participants’ knowledge of their allocation may affect compliance, response, and/or reporting of outcomes. Patient management could also be altered if health care workers acquire this information (Forder et al 2005). Such knowledge could further affect how assessment data are collected, interpreted and reported (Schulz and Grimes 2002c, Jadad and Enkin 2007). Double blinding is therefore considered to be the gold standard (Ukoumunne et al 1999, Forder et al 2005, Boehmer and Yong 2009, Friedman et al 2010), and empirical evidence suggests that, in trials where it is not included, treatment effects can be exaggerated by approximately 17% (Schulz et al 1995). 

Whereas allocation concealment is considered achievable (Schulz and Grimes 2002c, Forder et al 2005, Farrokhyar et al 2010), the feasibility of blinding varies (Cook 2009). Parker (2009) argues, however, that even when incomplete, blinding reduces potential biases that may be stronger than the treatment effect. It is usually possible to at least ensure blinded assessment of outcomes (Schulz and Grimes 2002c, Forder et al 2005). However, ‘open trials’ where all involved are aware of the allocation, can sometimes be the only option. In all cases, the use of objective outcome measures will limit the potential for bias (Schulz and Grimes 2002c, Forder et al 2005). 

Cluster randomisation
In most trials, the unit of randomisation is the individual (Jadad and Enkin 2007). In contrast, in a cluster RCT, groups of individuals are randomised to each study arm (Puffer et al 2005). For example, a number of centres might be studied, each of which is randomised to deliver either a new rehabilitation package to all its patients (Cluster 1) or to provide usual care (Cluster 2). 

Compared to individually randomised studies, cluster trials are more complex to design, as they must account for the fact that individuals in the same cluster are likely to have similarities (intra cluster correlation) (Ukoumunne et al 1999, Campbell et al 2004, Hayes and Moulton 2009). Selection bias can also be problematic as allocation concealment is difficult (Torgerson 2001, Hayes and Moulton 2009), and those recruiting participants will often have prior knowledge of the intervention allocated to the cluster. Despite such criticisms, cluster randomisation can reduce the risk of cross contamination between groups (Torgerson 2001, MRC 2002, Puffer et al 2005, Hayes and Moulton 2009, Kramer et al 2009, Weijer et al 2011) and so can help avoid biased estimates of effect size (Ukoumunne et al 1999). 

Power, effect and sample size
Statistical predictions are used to determine the number of participants required in a trial. The basic requirements for sample size calculation can be seen in Table 4. Common practice is to power a RCT at 0.8 (80%), meaning that there is an 80% chance of detecting a true difference (Schulz and Grimes 2005a, Torgerson and Torgerson 2008) if one really exists. Increasing the power to >80% improves the probability that you can accept the hypothesis, that ‘a’ is better than ‘b’, reducing the risk of a Type I error (where you accept ‘a’ is better than ‘b’ when it is not). Conversely, reducing the power to <80% makes the opposite true, and increases the chance of a Type II error (where the hypothesis is incorrectly rejected) (Bland 1996). 
Insert Table 4 here: Components of sample size calculations (adapted from Schulz and Grimes (2005a)

Calculating sample size allows the chance of error to be accurately predicted and enables you to say to what level of confidence you can accept your hypothesis. Different assumptions about levels of alpha (Type I) error and power will alter the sample size required to determine an effect (Schulz and Grimes 2005a). Similarly, altering the required effect size will also impact on the sample size required. The effect size can be determined by the clinical importance of the difference and can be derived from previous work examining similar outcome measures (Schulz and Grimes 2005a). Where little information exists, a pilot trial may be required in order to provide the necessary data. 

Some trial designs require additional considerations. For example, in cluster trials, standard sample size calculations underestimate the number of participants required, because they allow for variation within but not between clusters (Ukoumunne et al 1999, Kramer et al 2009). To correct for this, it is necessary to multiply the estimated sample size by a quantity known as the design effect (Deff) (Donner et al 1981, Ukoumunne et al 1999). 

Attrition and Deviation
To avoid bias, the aim in every trial should be to include all randomly assigned participants in the primary analysis (Schulz and Grimes 2002d). Attrition can be minimised by good planning with proper training of research staff (Farrokhyar et al 2010), and a commitment to overcome challenges. Designs, which incorporate patient preference, may also reduce selective attrition (Table 5).
Insert Table 5 here: Designs incorporating patient preference 

Attrition and protocol deviations should be clearly reported, and ‘intention to treat analysis’ (where participants are analysed in the group to which they were randomised), should always be employed (Schulz and Grimes 2002d, Machin and Fayers 2010, Moher et al 2010, Schulz et al 2010) as it avoids biases associated with non-random loss of participants (Schulz and Grimes 2002d). Trials should be adequately powered at the start to take account of attrition (Farrokhyar et al 2010). This requires prior scrutiny of any available audit data so that possible reasons for and levels of attrition might be predicted and accounted for. 

Data analysis
The choice of statistical test(s) will depend on the outcome measures being studied and the type and level of data produced (for example nominal; ordinal; interval). Decisions should always be made in collaboration with a statistician. 

Testing for statistical significance using probability (p) values enables investigators to judge the likelihood that results have occurred by chance (Bland 1996). Conventionally, statistical significance is set at p< 0.05 (5% chance of error). Statistical significance alone does not, however, enable the clinical importance of results to be determined (Bland 1996). It is important therefore, to additionally calculate confidence intervals (the range within which the mean of the population likely falls). The narrower the interval, the greater the confidence investigators can have in their results. Odds ratios and relative risk (the likelihood of occurrence) can further assist in determining clinical significance, which may be important even if statistical significance is achieved.

Multiple analyses (including subgroup analyses) should be avoided. Such practice can increase the overall error in significance testing, as one or more of the tests will likely produce a false positive result, even with the use of statistical adjustments (Schulz and Grimes 2005b, Schulz and Grimes 2005c, Abdi 2007). Instead, Schulz and Grimes (2005b) argue that investigators should restrict the number of primary outcomes, and analyse only those specified in the protocol.  

Trial management
A steering group should be organised, whose role it is to oversee the management of the trial. It should include key stakeholders and should include representation from service users. Good trial management requires that regular meetings are held. Such forums offer the opportunity to discuss how the trial protocol will be operationalised, and to monitor whether the trial is proceeding according to the protocol. They also enable informed decisions regarding amendments, such as increasing the data collection period, or stopping earlier than planned, to be made at a timely point.  

There are a number of practical issues that should be considered before recruitment commences. These include how and by whom participants will be recruited, and who will collect data. For example, decisions about whether resources permit recruitment/data collection over weekends and out of hours, and who will provide cover during sickness and holiday periods will need to be made. Data management and storage arrangements should also be in place in accordance with the Data Protection Act (HMSO 1998). This will require the research team to ensure that secure facilities are available to store research data and that proper documentation is maintained.   

Challenges and solutions
It can be difficult to obtain the necessary funding to conduct a robust trial, particularly if you are are a novice researcher. The development of support systems such as the Research Design Service (RDS) (National English network funded by the Department of Health) (eg NIHR 2012a), and the growing recognition of the value of RCTs for nursing interventions is helping to improve this situation. Collaboration with more experienced researchers and setting up inter-professional research teams, which include service users, will further increase chances of success. 

Research governance processes (ethics, local research and development approvals) can often be lengthy and cause delays to the planned start date of a trial. This needs to be considered during the planning stage. It can be frustratingly difficult to gain ethical approval for interventions often viewed by the research team as non-interventional and unlikely to cause harm. There is also a growing requirement for patient and public involvement in the design and management of research, and a greater awareness of the benefits that their inclusion offers (Morrow et al 2012). Early collaboration with and active involvement of service users will increase the likely success of a trial. Services such as the ‘Enabling Involvement Fund’, offered by the RDS (NIHR 2012b), help facilitate active partnerships between service users and researchers maximising the opportunity to prioritise, design and manage ethical RCTs, considered to be of value by those at whom the intervention will be targetted (NIHR 2012b).    

Achieving the required sample size can be problematic in any trial. Veledø and Lomborg (2011) identified recruitment problems in almost 50% of the eight nurse led RCTs they reviewed. These problems were primarily caused by an unwillingness to promote or discuss the study with potential participants, poor planning, and inadequate resources (Veledø and Lomborg 2011), leading to problems with participant recruitment and follow up. Such data highlight the importance of early and ongoing collaboration before and throughout the trial period between the research team and clinical staff (Veledø and Lomborg 2011). 

The registration of planned trials on the controlled clinical trials register (Current controlled trials 2012), and clear, unambiguous reporting of processes and subsequent results is vital to ensure that those responsible for future research, policy and practice decisions remain cognisant of current work. Guidelines for the reporting of trials are available on the Consolidated Standards of Reporting Trials (CONSORT) website (CONSORT 2012) and have been widely published (Schulz et al 2010). CONSORT provide a 25 item checklist and a flow diagram, to be used by those reporting a trial, so that readers can understand how the trial was designed, conducted, analysed and interpreted, and to assess the validity of its results (CONSORT 2012). 

Conclusion
Well-conducted RCTs provide valuable research data, which can contribute to the development of effective nursing interventions (Richards and Hamers 2009). Nurse researchers are strongly encouraged to design, conduct and report trials in accordance with the requirements of the CONSORT reporting guidelines (Moher et al 2010, Schulz et al 2010). Such practice will minimise biases and increase the chance of publication, thus ensuring effective dissemination of important research findings. 
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